IMR Press / RCM / Volume 11 / Issue 1 / DOI: 10.3909/ricm0535

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Pitavastatin: The Newest HMG-CoA Reductase Inhibitor
Show Less
1 The David Geffen School of Medicine, UCLA Preventative Cardiology Program, University of California at Los Angeles, Los Angeles, CA
Rev. Cardiovasc. Med. 2010, 11(1), 26–32; https://doi.org/10.3909/ricm0535
Published: 30 March 2010
Abstract
Statins were first introduced in the 1980s as a treatment of hypercholesterolemia. They provide a remarkable array of clinical benefits, including the reduction of low-density lipoprotein cholesterol, total cholesterol, and triglycerides, and elevation of high-density lipoprotein cholesterol. The US Food and Drug Administration has recently approved a new statin—pitavastatin—for launch in 2010. In several clinical trials, pitavastatin has shown favorable clinical efficacy, a positive safety profile, and encouraging clinical experience in Japan and other parts of Asia.
Keywords
Coronary heart disease
HDL cholesterol
LDL cholesterol
Statins
Triglycerides
Share
Back to top